Odysight in the first quarter: backlog is visible, revenue is still missing

Odysight opened 2026 with a gap that is hard to dismiss as seasonality: roughly $14 million of backlog on one side, and only $82 thousand of revenue on the other. The 96% revenue decline from the comparable quarter looks dramatic, but it is also misleading, because the first quarter of 2025 included the accounting derecognition of a $1.69 million contract liability related to an old Fortune 500 medical customer. The real issue is different: the company is pointing to stronger defense interest, named customers, and booked backlog, but almost none of that has yet moved into reported revenue or cash. At the same time, sales and marketing expenses rose to $962 thousand, inventory increased to $313 thousand, and operating cash flow was negative $4.3 million. The cash position is still reasonably comfortable, at $21.8 million at the end of March, and the company has no material financial debt, but at the current quarterly burn rate that cash mainly buys time for commercialization. The next few quarters are therefore not a test of an AI story or a hot defense vertical. They are a simpler execution test: whether backlog turns into deliveries, recognized revenue, and cash collection.

The old medical customer is no longer the anchor

Odysight sells real-time visual monitoring solutions for critical components in locations that are difficult or unsafe to inspect during normal operations. Its product combines small visual sensors, embedded software, and AI/ML algorithms, and targets predictive maintenance and condition-based monitoring across industrial, aviation, automotive, and defense applications. The customer and user list disclosed by the company includes the Israeli Air Force, the Israeli Ministry of Defense, a global defense contractor, NASA, Israel Railways, and a leading European elevator-monitoring provider. That makes the company less a clean software vendor and more a technology commercialization company with hardware, installations, institutional customers, and long sales cycles.

The important transition is away from the historical medical-sector anchor and toward defense and industrial platforms. In the first quarter of 2025, revenue still benefited from an unusual accounting item tied to the old medical customer: the company recognized the remaining $1.69 million contract liability after it had not received a purchase order and did not expect to receive one. The same move also derecognized a $957 thousand contract fulfillment asset and included a $203 thousand inventory impairment. So the simple comparison between $82 thousand of revenue and $2.07 million in the comparable quarter does not only describe business deterioration. It mostly separates a one-time accounting revenue item from the operating platform business the company now has to prove.

The defense environment cuts both ways. On one side, the company describes delays in finalizing orders and delivering existing projects because of the war and regional escalation. On the other, it reports growing interest from Israeli government agencies and R&D programs, partly tied to more intensive flight hours and a larger defense budget. That does not offset the low revenue, but it explains why backlog matters more than quarterly revenue alone. The business signal is more positive than the top line, but the level of proof is still limited.

The backlog exists, conversion barely does

The number holding the story together is backlog, not quarterly revenue. As of March 31, 2026, the company reported backlog of approximately $14.0 million, compared with approximately $13.8 million at the end of 2025. Remaining performance obligations, or RPO, were also approximately $14 million. Backlog is defined as booked orders based on purchase orders or hard commitments, but the company makes clear that orders may be canceled, delayed, or reduced. Backlog is therefore a commercial asset, not guaranteed cash.

That gap sharpens what investors should test over the next few quarters. First-quarter revenue came mainly from customization and development services recognized over time, $77 thousand out of the total $82 thousand. That means the backlog has not yet moved into meaningful platform deliveries. Unbilled receivables also increased only from $615 thousand to $649 thousand, a small move relative to the backlog. A commercialization-stage company can look like this before a revenue step-up, but only if the following quarters show a clear movement from orders to manufacturing, delivery, invoicing, and collection.

Inventory offers a small sign that the company may be preparing for deliveries, but not enough to turn the quarter into proof. Inventory increased from $50 thousand at the end of 2025 to $313 thousand at the end of March, including $268 thousand of finished goods. No inventory impairment was recorded during the quarter. That can support upcoming deliveries, but without revenue and collection it also increases timing exposure. In this kind of company, inventory is not just a balance-sheet line. It is a working-capital test of whether growth consumes cash before it produces cash.

Cash allows investment, but burn increased

The relevant cash frame here is all-in cash flexibility: what is left after the quarter’s actual cash uses, including operating activity, investment, financing flows, and lease cash included in the operating picture. This is not a normalized maintenance cash-generation estimate, because the company is not yet a mature business that can be measured on maintenance economics. In the first quarter, the picture is straightforward: cash declined, and the decline came mainly from operating burn rather than heavy capital expenditure.

The balance sheet is still not classically stressed. Total liabilities were only $3.5 million against shareholders’ equity of $21.2 million, and the company does not show material financial debt. Future lease payments under the maturity schedule total $707 thousand, and cash paid for leases during the quarter was $156 thousand. The problem is not an imminent debt wall. It is the spending rate versus the commercialization rate. If negative operating cash flow of roughly $4.3 million per quarter continues without a revenue step-up, even a $21.8 million cash position quickly becomes a question about the next financing.

Capital movements during the quarter do not change that picture. The 2023 warrants were exercised in March 2026 on a cashless basis and added 407,497 shares, but did not bring in material cash. Cash proceeds from option exercises were only $32 thousand. At the same time, stock-based compensation expense was $886 thousand, including roughly $400 thousand tied to the extension of certain option terms. That is not a cash line, but it reinforces the stage of the business: the company is funding people, commercialization, and compensation before revenue supports the cost base.

The next quarters must show the move from demand to execution

Two post-balance-sheet events matter for the next read. The first is the start of trading in Tel Aviv on April 9, 2026, alongside the Nasdaq listing. That gives the company a more natural Israeli investor base for an Israeli defense-oriented technology name, but it also adds the risk of price and liquidity differences between the two exchanges. The second is the appointment of Ronen Tanami as Chief Operating Officer on May 13, 2026, after he had served as interim VP R&D from the start of January. For a company whose test has shifted from technology capability to operational conversion of backlog, that appointment is directly connected to the active bottleneck.

Odysight has a more real growth story than first-quarter revenue suggests, mainly because of backlog and defense interest. But it has not yet shown that this backlog converts into revenue pace, meaningful gross profit, or cash flow. A better read needs three proof points: revenue rising against backlog, cash burn moderating or being justified by near-term deliveries and collection, and defense-related delays looking like timing issues rather than a persistent blocker. The counter-thesis is clear: if customers keep pushing out orders and spending rises before commercialization arrives, cash will buy time but not change the quality of the business. That will determine whether the first quarter was a transition quarter on the way to commercialization, or evidence that the gap between reported demand and actual revenue is still too wide.